Objective: The authors compared the performance of a novel self-collect device with clinician-collected samples for detection of high-risk human papillomavirus (hrHPV).
Materials And Methods: Eighty-two (82) participants were recruited from 5 clinical sites in the United States. Each participant performed self-collect sampling using the self-collect device followed by a standard of care clinician-collected sample.
Background: We evaluated letermovir (LTV) for secondary prophylaxis for cytomegalovirus (CMV) in allogeneic hematopoietic cell transplant recipients (HCT) at high-risk for CMV recurrence.
Methods: Open-label study conducted at Memorial Sloan Kettering Cancer Center and the University of Minnesota. Patients with clinically significant CMV infection (cs-CMVi) and ≥1 high-risk criteria for CMV who achieved viral suppression with standard CMV antivirals, received letermovir (LTV) secondary prophylaxis for up to 14 weeks.
Yield validation of dinitrogen reduction reaction (NRR) catalysts with N isotope labeling experiments is frustrated by the high cost of N and the frequent occurrence of NH and NO impurities in commercial N sources. Also, gas diffusion electrode (GDE) cell architectures are relevant to scaling NRR but underexplored and limited by ex situ product analysis methods. To overcome these obstacles, we develop and demonstrate a protocol for NRR catalyst testing using a scalable GDE cell architecture and specialized test station that facilitates in-line product analysis with multiturn time-of-flight mass spectrometry.
View Article and Find Full Text PDFBackground: This study aims to elucidate ancestry-specific changes to the genomic regulatory architecture in induced pluripotent stem cell (iPSC)-derived oligodendroglia, focusing on their implications for Alzheimer's disease (AD). This work addresses the lack of diversity in previous iPSC studies by including ancestries that contribute to African American (European/African) and Hispanic/Latino populations (Amerindian/African/European).
Methods: We generated 12 iPSC lines-four African, four Amerindian, and four European- from both AD patients and non-cognitively impaired individuals, with varying genotypes ( and ).